{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:50:27Z","timestamp":1786740627548,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Sitagliptin is an incretin enhancer used for treating type 2 diabetes mellitus. This review examined the pharmacokinetics (PK) of sitagliptin in healthy and diseased subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Articles related to sitagliptin PK were obtained by searching Google Scholar, PubMed, Cochrane Library, and ScienceDirect. In total, 24 clinical studies encompassing plasma concentration\u2013time profile data after oral and intravenous (IV) administration of sitagliptin were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sitagliptin displays a linear PK profile in healthy subjects as area under the concentration\u2013time curves from zero to infinity (AUC\n                      <jats:sub>0\u2013inf<\/jats:sub>\n                      ); the maximum plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) increases with dose. Its AUC\n                      <jats:sub>0\u2013inf<\/jats:sub>\n                      after IV administration (3692.5 \u00b1 504.9 ng\u00b7h\/mL) and oral dosing (3217.8 \u00b1 496.9 ng\u00b7h\/mL) indicates an oral bioavailability of \u223c87%. Its renal clearance is significantly reduced in patients with moderate hepatic impairment compared with that in healthy subjects (clinically insignificant owing to sitagliptin's wide therapeutic index and predominant renal elimination; dose adjustment is generally not required). Its C\n                      <jats:sub>max<\/jats:sub>\n                      is 162.93 \u00b1 37.16 and 181.75 \u00b1 33.44 ng\/mL in fasting and fed states, respectively, representing a 1.12-fold increase with food intake (clinically insignificant). Sitagliptin AUC\n                      <jats:sub>0\u2013inf<\/jats:sub>\n                      is 3.5-fold greater in patients with chronic kidney disease than in healthy subjects. Sitagliptin coadministration with gemfibrozil increases its exposure (C\n                      <jats:sub>max<\/jats:sub>\n                      increases from 282.9 \u00b1 18.9 to 344.1 \u00b1 14.5 ng\/mL; AUC\n                      <jats:sub>0\u2013inf<\/jats:sub>\n                      increases from 3621 \u00b1 222.5 to 5574 \u00b1 611.5 ng\u00b7h\/mL). Moreover, dorzagliatin does not alter sitagliptin PK parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This review summarizes the available PK data on sitagliptin from published studies in healthy and diseased subjects. These data may be useful for developing physiologically based PK models and may provide additional information to support clinicians in optimizing sitagliptin dosing in patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001506","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:24:50Z","timestamp":1786739090000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Clinical Pharmacokinetics of Sitagliptin in Healthy and Diseased Populations: A Systematic Critical Review"],"prefix":"10.1097","author":[{"given":"Tahir","family":"Saleem","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Saeed","sequence":"additional","affiliation":[{"name":"University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, Lahore, Pakistan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"R1-20260814","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003495-200767040-00007","article-title":"Sitagliptin","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"key":"R2-20260814","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/14779072.2015.1046840","article-title":"Sitagliptin for type 2 diabetes: a 2015 update","volume":"13","author":"Lee","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R3-20260814","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1111\/jcmm.15501","article-title":"Sitagliptin improves functional recovery via GLP\u20101R\u2010induced anti\u2010apoptosis and facilitation of axonal regeneration after spinal cord injury","volume":"24","author":"Han","year":"2020","journal-title":"J Cel Mol Med"},{"key":"R4-20260814","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","article-title":"Sitagliptin: a review in type 2 diabetes","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"R5-20260814","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4274\/tjps.galenos.2020.60863","article-title":"Development of an in vitro-in vivo correlation for sitagliptin and metformin prolonged-release tablet formulations","volume":"18","author":"Boddu","year":"2021","journal-title":"Turkish J Pharm Sci"},{"key":"R6-20260814","doi-asserted-by":"crossref","first-page":"117286","DOI":"10.1016\/j.saa.2019.117286","article-title":"Multispectral and computational probing of the interactions between sitagliptin and serum albumin","volume":"223","author":"Shaghaghi","year":"2019","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"R7-20260814","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1517\/14656566.2011.580738","article-title":"Sitagliptin: a review","volume":"12","author":"Subbarayan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R8-20260814","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double\u2010blind, placebo\u2010controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20260814","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3390\/ma12152351","article-title":"Solid-state characterization of different crystalline forms of sitagliptin","volume":"12","author":"Stofella","year":"2019","journal-title":"Materials"},{"key":"R10-20260814","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate","volume":"111","author":"Charoo","year":"2022","journal-title":"J Pharm Sci"},{"key":"R11-20260814","first-page":"217","article-title":"Analytical methods for determination of sitagliptin: an updated review","volume":"43","author":"Gracea","year":"2017","journal-title":"Int J Pharm Sci Rev Res"},{"key":"R12-20260814","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2146\/ajhp070248","article-title":"Sitagliptin: a novel agent for the management of type 2 diabetes mellitus","volume":"65","author":"Pham","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"R13-20260814","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1097\/MD.0000000000001128","article-title":"Sitagliptin after ischemic stroke in type 2 diabetic patients: a nationwide cohort study","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"},{"key":"R14-20260814","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CRD.0b013e318123f771","article-title":"Sitagliptin: a novel drug for the treatment of type 2 diabetes","volume":"15","author":"Choy","year":"2007","journal-title":"Cardiol Rev"},{"key":"R15-20260814","first-page":"e165","article-title":"Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin","volume":"16","author":"Migoya","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"R16-20260814","doi-asserted-by":"crossref","first-page":"e8161","DOI":"10.1097\/MD.0000000000008161","article-title":"Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R17-20260814","doi-asserted-by":"crossref","first-page":"e017260","DOI":"10.1136\/bmjopen-2017-017260","article-title":"Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis","volume":"7","author":"Sharma","year":"2017","journal-title":"BMJ Open"},{"key":"R18-20260814","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2459\/JCM.0000000000001270","article-title":"Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Wu","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R19-20260814","doi-asserted-by":"crossref","first-page":"BSR20190980","DOI":"10.1042\/BSR20190980","article-title":"Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus","volume":"39","author":"Zeng","year":"2019","journal-title":"Biosci Rep"},{"key":"R20-20260814","doi-asserted-by":"crossref","first-page":"e17081","DOI":"10.1097\/MD.0000000000017081","article-title":"Efficacy and hypoglycemic risk of sitagliptin in obese\/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: a meta-analysis","volume":"98","author":"Dai","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R21-20260814","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R22-20260814","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s41182-019-0165-6","article-title":"A step by step guide for conducting a systematic review and meta-analysis with simulation data","volume":"47","author":"Tawfik","year":"2019","journal-title":"Trop Med Health"},{"key":"R23-20260814","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1460-9592.2008.02918.x","article-title":"Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children?","volume":"19","author":"Rubin","year":"2009","journal-title":"Paediatr Anaesth"},{"key":"R24-20260814","first-page":"31","article-title":"Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis","volume":"1","author":"Long","year":"2020","journal-title":"Res Methods Med Health Sci"},{"key":"R25-20260814","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11096-022-01390-y","article-title":"The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies","volume":"44","author":"Soliman","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"R26-20260814","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R27-20260814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther"},{"key":"R28-20260814","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0091270006289850","article-title":"Pharmacokinetics and pharmacodynamic effects of the oral DPP\u20104 inhibitor sitagliptin in middle\u2010aged obese subjects","volume":"46","author":"Herman","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R29-20260814","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1185\/030079906X132587","article-title":"Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes","volume":"22","author":"Herman","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R30-20260814","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2337\/dc06-2545","article-title":"Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor","volume":"30","author":"Bergman","year":"2007","journal-title":"Diabetes Care"},{"key":"R31-20260814","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0091270006296523","article-title":"Effect of a single cyclosporine dose on the single\u2010dose pharmacokinetics of sitagliptin (MK\u20100431), a dipeptidyl peptidase\u20104 inhibitor, in healthy male subjects","volume":"47","author":"Krishna","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R32-20260814","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bdd.560","article-title":"Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase\u20104 inhibitor, in healthy volunteers","volume":"28","author":"Bergman","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"R33-20260814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bdd.559","article-title":"Dose\u2010proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase\u20104 inhibitor, in healthy volunteers","volume":"28","author":"Bergman","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"R34-20260814","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/0091270009341653","article-title":"Multiple doses of sitagliptin, a selective DPP\u20104 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin","volume":"49","author":"Wright","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R35-20260814","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03256914","article-title":"Bioequivalence of sitagliptin\/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study","volume":"30","author":"Migoya","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R36-20260814","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00228-011-1177-2","article-title":"Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers","volume":"68","author":"Kp","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R37-20260814","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.2010.03852.x","article-title":"Evaluation of pharmacokinetic parameters and dipeptidyl peptidase\u20104 inhibition following single doses of sitagliptin in healthy, young Japanese males","volume":"71","author":"Herman","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R38-20260814","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12325-012-0055-3","article-title":"Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers","volume":"29","author":"Brand","year":"2012","journal-title":"Adv Ther"},{"key":"R39-20260814","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1463-1326.2012.01624.x","article-title":"No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects","volume":"14","author":"Smulders","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R40-20260814","first-page":"e356","article-title":"Effect of simvastatin on the pharmacokinetics of sitagliptin","volume":"19","author":"Cerra","year":"2012","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"R41-20260814","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00228-013-1475-y","article-title":"Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers","volume":"69","author":"Aquilante","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R42-20260814","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00228-018-2433-5","article-title":"Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males","volume":"74","author":"Sangle","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R43-20260814","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/pedi.12790","article-title":"A randomized clinical trial to evaluate the single\u2010dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes","volume":"20","author":"Fraser","year":"2019","journal-title":"Pediatr Diabetes"},{"key":"R44-20260814","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s40262-020-00886-y","article-title":"Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects","volume":"59","author":"Fouqueray","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R45-20260814","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.clinthera.2020.04.005","article-title":"An assessment of pharmacokinetic interaction between lobeglitazone and sitagliptin after multiple oral administrations in healthy men","volume":"42","author":"Moon","year":"2020","journal-title":"Clin Ther"},{"key":"R46-20260814","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40268-021-00371-2","article-title":"Pharmacokinetics and bioequivalence of sitagliptin phosphate\/metformin hydrochloride tablets in healthy chinese subjects: a randomized, open-label, crossover study","volume":"22","author":"Shi","year":"2022","journal-title":"Drugs R D"},{"key":"R47-20260814","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41467-023-36946-7","article-title":"A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"R48-20260814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13300-022-01349-2","article-title":"Bioequivalence evaluation in healthy volunteers: new generic formulations of sitagliptin and sitagliptin\u2013metformin fixed-dose combination compared with the originator products","volume":"14","author":"Schnaars","year":"2023","journal-title":"Diabetes Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:24:56Z","timestamp":1786739096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001506","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}